LBM.MI - Labomar S.p.A.
Labomar S.p.A.
Via N. Sauro, 35/l
Istrana, TV 31036
Italy
39 04 227312
https://labomar.com
Settore/i: Healthcare
Settore: Drug Manufacturers—Specialty & Generic
Impiegati a tempo pieno: 355
Figure dirigenziali chiave
| Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
|---|---|---|---|---|
| Dr. Walter Bertin | Founder, Chairman & CEO | N/D | N/D | 1959 |
| Claudio De Nadai | Exec. Director | N/D | N/D | N/D |
Descrizione
Labomar S.p.A. researches, develops, manufactures, and sells food supplements, medical devices, cosmetics, and pharmaceutical products in Italy, France, Poland, Spain, North America, and internationally. It offers food supplements for various therapeutic areas, including immune systems, gastroenterology, cough and cold, neurology, oncology, eyesight wellness, sport, dermatology, inside beauty, cardiology, orthopedics, pediatrics, detoxing, and metabolic syndrome; and vitamins, minerals, and antioxidants. The company also provides medical devices for the use in gynaecology, cough and cold, gastroenterology, wound healing, metabolic syndrome, proctology, detoxing, and oral wound care therapeutic areas; and foods for special medical purposes, such as gastroenterology, endocrinology, and dysphagia. In addition, it offers cosmetics for inside beauty, skin cleanser, skincare, haircare, oral wound care, sun care, dermatology, acne rosacea, acne, atopic dertmatitis, and bruises therapeutic areas; and probiotic food supplements. Further, the company provides contract development and manufacturing services. Labomar S.p.A. offers its products in the form of tablets, capsules, liquids, powders, and semi solids. It has a commercial agreement with Bayer for the development and production of the references in various pharmaceutical flavors and forms. The company was founded in 1998 and is headquartered in Istrana, Italy.
Governance aziendale
L'ISS Governance QualityScore di Labomar S.p.A. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.
